443 related articles for article (PubMed ID: 24203492)
1. The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells.
Zhu S; Denman CJ; Cobanoglu ZS; Kiany S; Lau CC; Gottschalk SM; Hughes DP; Kleinerman ES; Lee DA
Pharm Res; 2015 Mar; 32(3):779-92. PubMed ID: 24203492
[TBL] [Abstract][Full Text] [Related]
2. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3.
Ni L; Wang L; Yao C; Ni Z; Liu F; Gong C; Zhu X; Yan X; Watowich SS; Lee DA; Zhu S
Sci Rep; 2017 Mar; 7():45266. PubMed ID: 28338101
[TBL] [Abstract][Full Text] [Related]
4. Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity.
Yamanegi K; Yamane J; Kobayashi K; Kato-Kogoe N; Ohyama H; Nakasho K; Yamada N; Hata M; Nishioka T; Fukunaga S; Futani H; Okamura H; Terada N
Oncol Rep; 2010 Dec; 24(6):1621-7. PubMed ID: 21042760
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma.
Wu X; Tao Y; Hou J; Meng X; Shi J
Neoplasia; 2012 Dec; 14(12):1178-89. PubMed ID: 23308050
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
8. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.
Höring E; Podlech O; Silkenstedt B; Rota IA; Adamopoulou E; Naumann U
Anticancer Res; 2013 Apr; 33(4):1351-60. PubMed ID: 23564772
[TBL] [Abstract][Full Text] [Related]
10. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
11. The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
Desimio MG; Giuliani E; Doria M
Virology; 2017 Oct; 510():9-21. PubMed ID: 28689087
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of short-chain fatty acid propionate induces surface expression of NKG2D ligands on cancer cells.
Høgh RI; Møller SH; Jepsen SD; Mellergaard M; Lund A; Pejtersen M; Fitzner E; Andresen L; Skov S
FASEB J; 2020 Nov; 34(11):15531-15546. PubMed ID: 32996653
[TBL] [Abstract][Full Text] [Related]
13. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
15. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities.
Diermayr S; Himmelreich H; Durovic B; Mathys-Schneeberger A; Siegler U; Langenkamp U; Hofsteenge J; Gratwohl A; Tichelli A; Paluszewska M; Wiktor-Jedrzejczak W; Kalberer CP; Wodnar-Filipowicz A
Blood; 2008 Feb; 111(3):1428-36. PubMed ID: 17993609
[TBL] [Abstract][Full Text] [Related]
16. Functional Characterisation and Analysis of the Soluble NKG2D Ligand Repertoire Detected in Umbilical Cord Blood Plasma.
Cox ST; Danby R; Hernandez D; Laza-Briviesca R; Pearson H; Madrigal JA; Saudemont A
Front Immunol; 2018; 9():1282. PubMed ID: 29963042
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.
Satwani P; Bavishi S; Saha A; Zhao F; Ayello J; van de Ven C; Chu Y; Cairo MS
Cytotherapy; 2014 Oct; 16(10):1431-40. PubMed ID: 24856896
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate.
Chávez-Blanco A; De la Cruz-Hernández E; Domínguez GI; Rodríguez-Cortez O; Alatorre B; Pérez-Cárdenas E; Chacón-Salinas R; Trejo-Becerril C; Taja-Chayeb L; Trujillo JE; Contreras-Paredes A; Dueñas-González A
Int J Oncol; 2011 Dec; 39(6):1491-9. PubMed ID: 21805029
[TBL] [Abstract][Full Text] [Related]
20. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
Front Immunol; 2020; 11():40. PubMed ID: 32082316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]